Continued slow decay of the residual plasma viremia level in HIV-1-infected adults receiving long-term antiretroviral therapy

Journal of Infectious Diseases

Volumn 213, Issue 4, 2016, Pages 556-560

  Riddler, Sharon A ^a   Aga, Evgenia ^b   Bosch, Ronald J ^b   Bastow, Barbara ^e   Bedison, Margaret ^a   Vagratian, David ^a   Vaida, Florin ^f   Eron, Joseph J ^g   Gandhi, Rajesh T ^c,d   Mellors, John W ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Koch Institute for Integrative Cancer Research   (United States)

^e SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CD4 CD8 ratio; HIV AIDS; residual viremia; singlecopy assay; viral decay

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; BLACK PERSON; CAUCASIAN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE DOSAGE; HALF LIFE TIME; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVENOUS DRUG ABUSE; LONG TERM CARE; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; VIRAL DECAY; VIRAL PHENOMENA AND FUNCTIONS; VIREMIA; VIRUS LOAD; BLOOD; CD4 CD8 RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; PLASMA; PROCEDURES; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; PLASMA; RNA, VIRAL; VIRAL LOAD;

EID: 84960156454     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv433     Document Type: Article

References (15)

1. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5: 512-7
2. Siliciano JD, Kajdas J, Finzi D, et al. Long-Term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9: 727-8
3. Maldarelli F, Palmer S, King MS, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3: e46
4. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105: 3879-84
5. Zheng L, Bosch RJ, Chan ES, et al. Predictors of residual viraemia in patients on long-Term suppressive antiretroviral therapy. Antivir Ther 2013; 18: 39-43
6. Kearney MF, Spindler J, Shao W, et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog 2014; 10: e1004010
7. Smurzynski M, Collier AC, Koletar SL, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials 2008; 9: 269-82
8. Vaida F, Liu L. Fast implementation for normal mixed effects models with censored response. J Comput Graph Stat 2009; 18: 797-817
9. Lyles RH, Fan D, Chuachoowong R. Correlation coefficient estimation involving a left censored laboratory assay variable. Stat Med 2001; 20: 2921-33
10. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7
11. Maldarelli F, Wu X, Su L, et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 2014; 345: 179-83
12. Wagner TA, McLaughlin S, Garg K, et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 2014; 345: 570-3
13. Hatano H, Jain V, Hunt PW, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 2013; 208: 50-6
14. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10: e1004078
15. Cillo AR, Vagratian D, Bedison MA, et al. Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. J Clin Microbiol 2014; 52: 3944-51